TRULICITY 1.5 MG - AN OVERVIEW

The trial realized both its Key endpoints, with semaglutide 2.4 mg demonstrating statistically important and excellent advancements in liver fibrosis without any worsening of steatohepatitis, and also resolution of steatohepatitis without worsening of liver fibrosis in those with MASH compared to placebo.oneRetain all appointments using your doctor